… The importance of dysregulation of alveolar epithelial cells in the initiation of pulmonary
fibrosis has been strengthened by the recent observation that an IPF-associated mutation in the …

… candidates will be required to utilize different clinical development approaches, for a variety
… drug development efforts in pulmonary fibrosis by numerous companies, several drug …

… AECs are involved in pulmonary fibrosis (Figure 2A). … and development of pulmonary fibrosis.
The M2-mediated type 2 immune response is an important component of pulmonary fibrosis…

… diseases and use of the appropriate preclinical model system to test these will likely be
required to improve the drug development pipeline for pulmonary fibrosis. Combination with …

… Idiopathic pulmonary fibrosis (IPF) is a relentlessly progressive scarring disorder of the …
licensing in Europe and Asia of the first drug developed specifically for the treatment of IPF, …

… orphan drug and fast-track regulatory strategies currently available to drug developers. … ;
Roche) were approved by the US Food and Drug Administration (FDA), following, in the case of …

… development of experimental pulmonary fibrosis by inducing exaggerated alveolar epithelial
cell apoptosis, pulmonary … drug development in IPF remain, some of which are listed below. …

… currently being studied for IPF treatment and where they are in the drug development
pipeline. In addition to the promising lead compounds GLPG1690, BBT-877, and TD139 all …

… The understanding of IPF pathogenesis has significantly improved over the last two decades,
thus changing the approach to drug development. The previous paradigm considered IPF …

… In spite of substantial progress in drug development during the last century, there are still
many conditions that cannot be cured or even controlled. The need to find better therapeutics to …